Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Recruiting

Phase 1

Talazoparib & ChemotherapyStudy of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Sponsor:

Norman J. Lacayo

Code:

NCT05101551

Conditions

Acute Myeloid Leukemia

Eligibility Criteria

Sex: All

Age: 0 - 21

Healthy Volunteers: Not accepted

Interventions

Talazoparib

Topotecan

Gemcitabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-08. This information was provided to ClinicalTrials.gov by Norman J. Lacayo on 2025-05-29.